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ABSTRACT
A rapid and sensitive method for excluding the presence of methicillin-resistant Staphylococcus aureus
(MRSA) in clinical samples was developed and evaluated. The method utilised an MRSA-selective
enrichment broth for 16 h, followed by PCR quantiﬁcation of the nuc gene. Samples below a quantitative
PCR threshold were reported as MRSA-negative. Broths from PCR-positive samples were subcultured
for MRSA isolation. Clinical samples (n = 334) in a constructed high prevalence population were
analysed in parallel with a selective plating method. The new broth-PCR assay increased the number of
positive samples by 35% (49 vs. 66), and 94% of negative samples were reported within 24 h. To reduce
costs and workload, 665 clinical samples were grown separately in enrichment broth and then pooled in
the PCR step. The broth-PCR assay increased the number of MRSA positive samples from 11 to 15
compared with selective plating. Most (89%) of the culture-negative samples were also PCR-negative
and could be reported within 24 h. The growth of 25 European EMRSA strains was tested in the
selective enrichment broth. On average, the MRSA strains showed a 300 000-fold increase in CFU,
compared with 30-fold for the eight methicillin-sensitive Staphylococcus aureus strains tested.
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INTRODUCTION
In most parts of the world, the prevalence of
methicillin-resistant Staphylococcus aureus (MRSA)
in hospitals has reached levels where its occur-
rence has to be considered endemic [1]. The
associated problems of increased costs and mor-
tality are well-recognised [2–5]. Among the
exceptions are the Nordic countries and The
Netherlands, where the prevalence of MRSA is
<1% among staphylococci causing bacteraemia
(EARSS Annual Report 2001; http://www.earss.
rivm.nl).
A cornerstone in attempts to prevent an endemic
MRSA situation is screening [6]. Patients and staff
at risk of being infected or colonised are screened,
and ideally kept isolated, until they have been
declared free ofMRSA. Since some clones ofMRSA
have a well-documented capacity to spread in the
hospital environment [7,8], the surveillance net
must be effective. A large proportion of the
samples taken will be MRSA-negative. The time
between sampling and delivery of the result
inﬂuences workload and costs for isolation care.
There is an obvious need for a quick, but
sensitive, method for identifying MRSA. Every
day (or even half-day) saved will reduce costs and
workload, and also improve compliance with
screening schemes. Several methods have been
described that utilise PCR for detection of MRSA
directly from clinical specimens [9–11] or in
combination with broth enrichment [12,13]. Direct
detection enables shorter sample turn-around
time in the laboratory, but has the disadvantage
of requiring resampling and reanalysis with a
method based on cultivation if MRSA isolates are
needed for epidemiological analysis. A lower
sensitivity and speciﬁcity compared with culture
methods has also been reported.
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This paper presents an approach that is capable
of excluding the presence of MRSA in patient
samples in <24 h, with sensitivity superior to the
traditional selective plating method used cur-
rently in many laboratories. The method is based
on selective enrichment in a broth containing
methicillin. A quantitative nuc gene PCR is then
used to exclude the presence of MRSA in the
broth, based on the assumption that mainly
MRSA, and little else, would be able to multiply
in the selective broth. Samples positive in the PCR
screen are subcultured for MRSA isolation. The
possibility of pooling samples in the PCR step in
order to reduce workload and costs was exam-
ined, and, as clonal heterogeneity in the level of
expression of the methicillin resistance phenotype
has been described among MRSA isolates [14,15],
the ability of the selective broth to support the
growth of 25 European epidemic MRSA and eight
MSSA isolates was evaluated.
MATERIALS AND METHODS
Bacterial strains and patient samples
The standard MRSA strains (n = 25) were collected as repre-
sentative epidemic strains from various member countries in
the HARMONY network, and had at least three band differ-
ences in SmaI pulsed-ﬁeld gel electrophoresis (PFGE) patterns.
PFGE was performed as described by Bannerman et al. [16].
The following strains were used: Belgium (BE-1 to BE-3) 97S99
(1432), 97S100 (95 ⁄ 3511 ⁄ 4) and 98S46 (95 ⁄ 1106 ⁄ 2); Finland (FI-1
to FI-6) 61974, 37481, 62396, 75541, 76167 and 54511; France
(FR-1 to FR-4) 920, 162, 10828 and 10882; Germany (GE-1 to
GE-6) 1442 ⁄ 98, 1450 ⁄ 94, 1155–2 ⁄ 98, 1000 ⁄ 93, 134 ⁄ 93 and 825 ⁄ 96;
Greece (GR-1) 3680; Sweden (SW-1) AO9973 ⁄ 97; UK (UK-1 to
UK-4) 90 ⁄ 10685, M307, NCTC11939 and 96 ⁄ 32010. Further
information on these strains is available on the HARMONY
network homepage (http://www.harmony-microbe.net/
index.htm).
Seven of the eight MSSA strains used in the study were
collected at the Department of Clinical Microbiology, The
County Hospital of Halmstad, Sweden. HY54037 ⁄ 00,
HY45802 ⁄ 00 and HY54058 ⁄ 00 were isolated from the anterior
nostrils of women immediately upon admission to hospital for
childbirth. A44138 ⁄ 00, A36655 ⁄ 00, A44130 ⁄ 00 and A100363 ⁄ 99
were isolated from patients with manifest infections during
routine diagnostic laboratory work. The strains selected had at
least three band differences in the SmaI PFGE banding
patterns. MSSA strain NCTC 8325 was also included in the
test panel.
Between August 2000 and August 2001, 334 MRSA
screening samples (77 nostril, 77 pharynx, 77 perineum,
47 wound, 33 urine and 23 from other sites) sent to the
laboratory were included in the study. Consecutive samples
from known MRSA carriers, together with samples from a
presumed negative patient collected on the same day, were
included. The 334 screening samples came from 49 different
patients (35 MRSA-negative and 14 MRSA-positive on at
least one occasion). Nine different MRSA clones, as deﬁned
by SmaI PFGE patterns, were represented among the 14
positive patients. A further 665 consecutive MRSA screening
samples sent to the laboratory between September 2001 and
November 2001 were included in the evaluation of pooled
samples. Samples were pooled in groups of three consecu-
tive samples.
Selective enrichment broth
The selective enrichment broth (MAM broth) used was based
on a solid screening medium for MRSA (MAMSA) described
by Perry et al. [17]. One litre of MAM broth contains 15 g
proteos peptone (Oxoid, Basingstoke, UK), 2.5 g liver digest
(Oxoid), 5 g yeast extract (Oxoid), 25 g NaCl, 10 g mannitol,
phenyl red 16 mg ⁄L, 2.0 mg methicillin and 8 mg aztreonam
(ﬁnal pH 7.0 ± 0.1).
Growth test of deﬁned strains
Single colonies of S. aureus grown on blood agar were
transferred to 5 mL of brain-heart infusion broth and grown
overnight at 37C under aerobic conditions. The following
day, the culture was vortexed vigorously and an aliquot was
diluted serially 102, 103, 104 and 105-fold. The inoculum size
was determined from the 102 dilution using quantitative
real-time nuc gene PCR (see below), and 50 lL of the dilutions
were inoculated into 5 mL of MAM broth. The cultures were
incubated in a shaker for 16 h at 37C under aerobic
conditions. To release DNA for PCR analysis, the cultures
were harvested by centrifugation, and the bacterial cell pellet
was resuspended in 2.5 mL lysis buffer (20 mM Tris-HCl,
pH 7.6, Tween 20 (Sigma-Aldrich, Steinheim, Germany) 0.5%
v ⁄v, Igepal CA-630 (Sigma-Aldrich) 0.5% v ⁄v and
proteinase K (Roche Diagnostics, Indianapolis, IN, USA)
60 mg ⁄L. For cell lysis, the suspension was incubated at
56C for 1.5 h, followed by proteinase K inactivation at 95C
for 5 min [18].
Clinical samples
All clinical samples were inoculated on to MAMSA plates [17]
and incubated at 37C. The swab was then submerged in a
tube containing 5 mL of MAM broth. The MAMSA plate was
inspected after 24 and 48 h, and suspected staphylococcal
colonies were isolated and analysed further. The broth was
incubated for 16 h in a shaker at 37C under aerobic condi-
tions. Following incubation, a 100-lL aliquot was withdrawn
for PCR analysis. The cells were harvested by centrifugation
and the resulting pellet was suspended in 50 lL lysis buffer.
The suspension was then incubated at 56C for 1 h, followed
by proteinase K inactivation at 95C for 5 min. In the second
part of the study, samples were incubated separately in MAM
broth, after which 100-lL aliquots from up to three samples
were pooled. Cells were harvested by centrifugation, suspen-
ded in 150 lL lysis buffer, and then incubated as described
above.
For subculturing of broth cultures, 1 lL was spread on to a
blood agar plate without any supplement, a blood agar plate
containing lithium chloride 0.5%w ⁄v to suppress the growth of
enterococci, and a blood agar plate containing colistin 24 mg ⁄L
to suppress the growthof coagulase-negative staphylococci [19].
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These plates were incubated at 37C overnight and then
inspected for growth of staphylococcal colonies. Suspected
MRSA isolates were tested by mecA ⁄ nuc gene PCR (see below).
PCR analysis
For validation purposes, a 10-fold dilution series, with
0.3–3 · 106 CFU ⁄PCR reaction, was used. The concentration
of bacterial cells was based on viable count determinations on
blood agar plates. The suspension of bacteria was prepared for
PCR as described for clinical samples, and the serial dilutions
were made in the lysis buffer described above, but without
addition of proteinase K.
Before PCR analysis, aliquots of lysates were centrifuged for
1 min at 9000 g, and 2 lLwas subjected to quantitative real-time
nuc gene PCR. The 20-lL reactionmix consisted of PCR reaction
buffer (Roche Diagnostics), DMSO 2% v ⁄v, BSA (Roche Diag-
nostics) 0.01% w ⁄v, 0.6 · SybrGreen I (Molecular Probes,
Leiden, The Netherlands), 0.5 lM each of the oligonucleotide
primers (NUC1–5¢-GCGATTGATGGTGATACGGTT; NUC3–
5¢-CAAGCCTTGACGAACTAAAGC) (Scandinavian Gene
Synthesis, Ko¨ping, Sweden), 4 mM MgCl2, 200 lM dNTPs
(Roche Diagnostics), and 0.04 U ⁄ lL of FastStart TaqPolymerase
(Roche Diagnostics). The primers used for nuc gene ampliﬁca-
tion were those described by Brakstad et al. [20], with the
exception of the NUC3 reverse primer, which was shortened by
three nucleotides at the 5¢-end, compared with the published
sequence. The reaction mix was incubated in a LightCycler
(Roche Diagnostics), with preincubation at 95C for 10 min
followed by 35 cycles of 95C for 15 s, 65C for 5 s and 72C for
12 s. Fluorescence values for each capillary were measured at
530 nmat the endof each extension phase. Each experimentwas
completed by a melting point analysis: 95C for 0 s (hold time)
with 20C ⁄ s transition rate, 60C for 30 s with 20C ⁄ s transition
rate, 70C for 0 s (hold time) with 20C ⁄ s transition rate, and
90C for 0 s (hold time) with 0.2C ⁄ s transition rate, with
continuous acquisition of ﬂuorescence data at 530 nm.
The number of cells carrying the nuc gene in the lysates was
determined by comparing the crossing-point of each sample
with a standard curve. The standard curve consisted of
suspensions of MRSA cells at known concentrations
(CFU ⁄mL), as determined by viable counts on blood agar,
determined as described above. Three standard concentrations
(3.2 · 104, 3.2 · 106 and 3.2 · 108 CFU ⁄mL) were assayed in
each LightCycler experiment, and the resulting crossing-point
values were used to generate the standard curve.
Veriﬁcation of MRSA identiﬁcation was done by ampliﬁ-
cation of the nuc gene and the mecA gene. One colony was
suspended in 50 lL lysis buffer and lysed, followed by
ampliﬁcation of the nuc gene as described above. The mecA
gene was ampliﬁed using the same protocol, but using
primers MEC3 (5¢-GCAATCGCTAAAGAACTAAG) and
MEC4 (5¢-GGGACCAACATAACCTAATA) (Scandinavian
Gene Synthesis) to amplify a 222-bp fragment of the mecA
gene. This fragment had a melting peak at 81.6C (average of
15 separate runs of control strain; range 81.2–82.1C; standard
deviation 0.23C) in the melting point analysis.
Control for PCR inhibition
In total, 100 consecutive sample pools (240 samples) were
tested for possible inhibition. A bacterial lysate, prepared as
described above from two or three pooled samples, was
seeded with a diluted lysate from a positive MRSA strain
(CCUG 35600). The seeded lysate contained MRSA DNA,
corresponding to c. 105 CFU ⁄mL. As a reference sample, lysis
buffer without bacteria was seeded with the same amount of
positive material. The samples were analysed in the LightCy-
cler as described above, and crossing-points were calculated.
Using this approach, inhibition in a sample is seen as a higher
crossing-point value than for the reference sample.
RESULTS
Validation of nuc gene PCR
The speciﬁcity of the nuc gene PCR [20] in the
SybrGreen format was established by analysing
the size of the amplicons generated with a
positive control strain (MRSA CCUG 35600).
Ampliﬁcation produced a DNA fragment of the
expected size (276 bp), as determined by gel
electrophoresis, which corresponded to a melting
peak at 82.6C (average of 50 separate runs of the
control strain; range 81.6–84.2C; standard devi-
ation 0.44C). A peak of lower melting tempera-
ture was also observed in positive samples, but
not in negative samples (Fig. 1) or the negative
control, as would be expected if it were the result
of primer-dimer ampliﬁcation.
The detection level, PCR efﬁciency and linear-
ity of the nuc gene PCR was investigated by
analysing dilutions of MRSA CCUG 35600 con-
taining known numbers of CFU. Fig. 2 shows the
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Fig. 1. Melting point analysis of nuc gene ampliﬁcation
reaction with MRSA control strain and patient samples as
template. Melting peak at 82.6C corresponds to the 276-bp
nuc amplicon. Black line, standard MRSA CCUG 35600
(viable count of 1.6 · 109 CFU ⁄mL); grey line, patient
sample quantiﬁed to 1.3 · 107 CFU ⁄mL; broken black line,
patient sample quantiﬁed to 1.0 · 103 CFU ⁄mL; dotted
line, negative patient sample.
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crossing-point values plotted against triplicate
values of dilutions ranging from 3 to
3 · 106 CFU ⁄PCR. All triplicates down to
30 CFU ⁄ reaction generated ampliﬁcation curves,
and two of three were positive with 3 CFU ⁄ reac-
tion. No ampliﬁcation occurred with the dilution
containing 0.3 CFU. The reaction was linear over
at least ﬁve orders of magnitude, with an R2
value of 0.9999, based on the average crossing-
point value for triplicates containing 30–
3 · 106 CFU ⁄ reaction. The slope of the regression
line was )3.41, corresponding to a PCR efﬁ-
ciency of 96%.
In order to validate the quantitative real-time
nuc gene PCR, a separately prepared MRSA
control containing 6.7 · 105 CFU ⁄mL was pre-
pared. This standard was quantiﬁed in ten sep-
arate runs from a three-point standard curve. The
mean number of cells in the standard was
5.57 · 105 CFU ⁄mL (range, 4.5 · 105)7.1 · 105
CFU ⁄mL; standard deviation, 7.98 · 104; coefﬁ-
cient of variation, 14.3%). The accuracy was
)16.4% (5.6 · 105)6.7 · 105 ⁄ 6.7 · 105 = )0.164).
Evaluation of MAM broth with deﬁned strains
The growth of 25 standard epidemic MRSA
strains and eight clinical isolates of MSSA was
tested as described in Methods. The initial inocu-
lum for the 25 MRSA strains varied between 200
and 1900 CFU ⁄mL (mean 908 CFU ⁄mL), while
that of the eight MSSA isolates was between
450 and 9850 CFU ⁄mL (mean 2550 CFU ⁄mL).
Fig. 3 shows the increase in cell-count for each
strain after incubation for 16 h. On average, the 25
MRSA strains showed a 3 · 105-fold increase
(range 4000–1.7 · 106), compared with 30-fold
(range 0–130-fold) for the eight MSSA isolates.
All MRSA strains tested were able to multiply in
the broth to a greater extent than the tested MSSA
isolates.
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Fig. 2. Linearity of the nuc gene ampliﬁcation. Triplicates
of dilutions ranging from 0.3 to 3 · 106 CFU ⁄ reaction were
ampliﬁed. No ampliﬁcation occurred with 0.3 CFU ⁄ reac-
tion. Two of three triplicates were positive with
3 CFU ⁄ reaction. Regression line shown is calculated from
the average of triplicates (duplicate for 3 CFU dilution) for
the different dilutions. R2 = 0.9999.
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Fig. 3. Fold-increase in cell counts for 25 MRSA and eight MSSA following incubation for 16 h in MAM broth. Black bars,
MRSA; grey bars, MSSA.
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Analysing clinical samples
The enrichment-PCR method described here was
compared with a sensitive selective plating
method [17]. In order to evaluate the sensitivity
within a reasonable time, a series with a high
prevalence (20%) of MRSA-positive samples was
created. Sample series from known MRSA-posit-
ive individuals were included consecutively in
the study, together with an additional sample
series from a presumed MRSA-negative individ-
ual. Between August 2000 and August 2001, 334
clinical samples were analysed with both meth-
ods. In total, MRSA was isolated from 67 of the
334 samples with either of the methods; 66 after
enrichment followed by subculturing, and 49
following inoculation on to a MAMSA plate.
The broth failed to detect one positive sample
(Table 1).
With the aim of using the nuc gene PCR as a
screening tool, a cut-off for MRSA negativity was
deﬁned. As shown in Fig. 4, all samples
from which MRSA was isolated contained
>1 · 105 CFU ⁄mL. It was concluded that samples
containing <5 · 104 CFU ⁄mL could safely be con-
sidered negative for MRSA. Using the value of
5 · 104 CFU ⁄mL as the cut-off for positivity, the
PCR step identiﬁed all MRSA-containing broth-
cultures with a speciﬁcity of 94% (Table 1; Fig. 4).
Thus, 94% of the negative samples, in this
constructed 20% prevalence population, were
reported within 24 h. The remaining negative
and positive samples required an additional
24 h before becoming conclusive. Seventeen
samples which, according to the PCR, contained
>5 · 104 CFU ⁄mL, failed to yield MRSA colonies
on the MAMSA plate or from the MAM broth. In
most of these cases, MSSA colonies were obtained
after subculturing the broth.
The frequency of MRSA-positive results from
the nostril, pharynx and perineum screening sites
increased by 76% (from 17 to 30 positives)
following use of an enrichment broth. In contrast,
the rate only increased by 13% (from 32 to 36
positives) for sites at which infection rather than
colonisation was expected (Table 2).
These results were obtained by performing one
PCR for each clinical sample. In order to reduce
the workload and cost for the laboratory, the
possibility of pooling samples for the PCR step
was investigated. All swabs (n = 665) were ﬁrst
inoculated on to a MAMSA plate and then
immersed in selective broth. Broth cultures from
three consecutive samples were pooled in the
PCR step and then analysed by quantitative nuc
gene PCR, although only those samples that were
positive above the threshold were subcultured on
to agar plates for MRSA isolation. Based on the
threshold deﬁned previously, and the assumption
that a single positive sample in a pool with two
negative samples would be diluted three-fold, a
threshold of 5.0 · 104 ‚ 3 = 1.7 · 104 CFU ⁄mL
was used. Of 665 samples analysed, MRSA was
isolated from 15, leaving 650 negative samples. Of
these, 579 (89%) were below the cut-off point in
the PCR analysis. All 15 positive samples were
positive by PCR, and MRSA was isolated from the
Table 1. Comparison of the performance of the selective
MAMSA plate (MAMSA), the real-time nuc gene PCR and
the selective MAM broth (BROTH) for isolation of MRSA
MAMSA PCR BROTH
True-positive 49 66 66
True-negative 267 250 267
False-positive 0 17 0
False-negative 18 1 1
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Fig. 4. Plot of Staphylococcus aureus counts (CFU ⁄mL)
determined by quantitative real-time PCR for a subset of
334 clinical samples (53 ⁄ 334) around the cut-off value of
50 000 CFU ⁄mL. The remainder of the samples were either
MRSA-positive with >1 · 109 CFU ⁄mL (38 ⁄ 334 samples)
or MRSA-negative and below the 1000 CFU ⁄mL detection
level of the method (243 ⁄ 334 samples). Black rectangles,
MRSA-positive samples; white triangles, MRSA-negative
samples.
Table 2. Body sites from which MRSA was isolated
following direct plating on a MAMSA plate and following
enrichment in selective broth (total of 334 clinical samples)
Nostril Pharynx Perineum Wound Urine Other
Plate 3 7 7 15 8 9
Broth 6 16 8 16 8 12
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broth, while 11 of 15 were positive on the
MAMSA plate.
Inhibition test
Consecutive pools (n = 100) of samples were
tested for inhibition following seeding with small
amounts of positive DNA lysate. On average, the
crossing-point value for seeded pools was 1.50
cycles higher than that for the reference sample.
The deviation from the reference sample was
within the range 0.36–3.86, with a standard
deviation of 0.78 (as a reference value, a ten-fold
dilution of a sample is expected to increase the
crossing-point value by c. 3.3, assuming a PCR
efﬁciency of 100%).
DISCUSSION
The method described in this paper has been in
regular use in this laboratory since November
2001, and the basic idea has also been adopted in
other clinical laboratories in Sweden [13]. The
method is based on the assumption that nuc-
carrying bacterial cells will proliferate in the
selective broth to a level above the deﬁned cut-
off when a mecA gene is present in the same cell
(MRSA). Initially, nuc-positive broth samples
were assayed for the presence of mecA genes,
but this had limited value (results not shown),
probably because of a high frequency of mecA
genes in coagulase-negative staphylococci present
in the samples.
Many different solid culture media [17,21,22]
and enrichment broth media [12,23–26] have been
described for the cultivation of S. aureus. Some
media include NaCl at high concentrations to
favour growth of staphylococci, although some
clones have a documented lower salt-tolerance
[27], as well as oxacillin or methicillin to make
them selective for MRSA. The new methicillin,
aztreonam and mannitol-containing broth med-
ium described in the present study was based on
MAMSA agar [17], with a relatively low NaCl
concentration. It was designed to selectively
enrich for MRSA after incubation overnight (for
16 h).
It is well-known that different strains of MRSA
express the methicillin-resistant phenotype at
different levels [14,15,28]. This largely unex-
plained property must be taken into account
when designing selective media for MRSA, and
evaluations should include appropriate relevant
strains. The present study used part of the
HARMONY collection of epidemic MRSA strains,
and demonstrated that all tested strains (n = 25)
were able to multiply in the enrichment broth
described above. Although the inoculum sizes
varied for the different strains, no correlation was
observed between inoculum size and the increase
in cell counts (results not shown). The main
conclusion was that all tested MRSA strains
multiplied to a greater extent than all tested
MSSA strains, even though the inoculum of the
MSSA strains was, on average, larger than that of
the MRSA strains. The performance of the broth
was not tested with very small numbers of MRSA
cells, but its good performance, especially with
throat samples, indicated a capacity to support
the growth of MRSA from clinical samples con-
taining low numbers of MRSA.
The relatively low selective pressure in the
broth allows some strains of MSSA to grow,
which will lead to false-positive PCR results, as
was the case for 6% of the 267 negatives when
analysing single samples, and 11% of the pooled
samples. MSSA was isolated from most of these
samples after subculture of the broth. Experience
indicates that it is necessary to keep the methicil-
lin concentration at a moderate level in order to
allow low-grade (or heterogeneously) resistant
MRSA clones to grow. It may be possible to
increase the speciﬁcity by using other selective
substances, e.g., ceftizoxime [26]. A sample con-
taining a large (>5 · 105 CFU ⁄mL) inoculum of
MSSA could also produce a false-positive PCR
result from non-viable cells, even without growth
of MSSA in the broth. MRSA was isolated after
direct plating of one of 67 positive samples on the
MAMSA plate, but not after broth enrichment.
The nuc gene PCR was also negative for this
sample. Since only a few colonies of MRSA were
seen on the MAMSA plate, the discrepancy might
be caused by the fact that the plate was inoculated
before the broth.
By pooling the samples in the PCR step, the
number of PCRs was reduced substantially, and
consequently the ‘hands on’ time and the volume
of PCR reagents were also reduced. Since only 32
samples can be analysed simultaneously in the
LightCycler, pooling also reduces machine usage
substantially. During evaluation, samples were
pooled consecutively, thereby grouping samples
from different patients in the same pool. Samples
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from MRSA-negative patients will be delayed if
pooled with samples from a positive patient. This
delay could be avoided simply by not mixing
samples from different patients.
In total, 100 sample pools (240 samples) were
tested for the presence of PCR inhibitors. Total
inhibition was not observed, and it was conclu-
ded that it would not be cost-effective to
introduce an inhibition control for all samples.
This is in agreement with the ﬁndings of Fang
et al. [13], who observed inhibition in only one
of 260 samples tested. The broth-PCR method
increased the detection rate substantially for
MRSA in samples from nostrils and throat, but
only slightly for samples from other sites. This
may be caused by low-level colonisation or
carriage of MRSA at these sites, which is below
the detection level of many conventional meth-
ods. This could explain, in part, why individu-
als colonised or infected with MRSA for longer
periods can test negative for weeks, and some-
times months, and then appear to be re-colo-
nised with the same clone.
Overall, the MRSA screening method described
in this report has several advantages. The ability
to exclude the presence of MRSA within 24 h will
reduce costs and workload, and also improve
compliance with screening schemes. Improved
sensitivity will result in fewer undetected MRSA-
positive patients and staff in the healthcare
system.
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